BioAmplified
All protocol guides
IntermediateRecovery11 min read

Recovery Protocols: BPC-157 and TB-500

How the two most-discussed repair peptides are structured together — local versus systemic action, sequencing, and the honest limits of the evidence.

Why these two are always mentioned together

BPC-157 and TB-500 are the reference compounds of the recovery category, and they are stacked for a specific structural reason rather than a fashionable one. BPC-157 appears to act locally — concentrating at the site of injury and driving angiogenesis there. TB-500 appears to act systemically, influencing cell migration and tissue remodelling throughout the body.

The logic of combining them is that one addresses the injury site and the other addresses the body's repair capacity. That logic is reasonable. It is also built entirely on preclinical work, which is the first thing to hold in mind.

The structural pattern

Recovery protocols in practice follow a rough shape:

  • Days 1 to 7: BPC-157 introduced alone, at the lower end of the reported range. This is a deliberate test for individual reaction.
  • Days 8 to 28: TB-500 added alongside, at a loading frequency of roughly twice weekly.
  • Weeks 5 to 8: TB-500 reduced to a maintenance frequency; BPC-157 continues if it is being well tolerated.
  • Weeks 9 onward: both discontinued, with a washout before any repeat course.

Introducing one compound at a time is not caution theatre. If you introduce both simultaneously and develop a reaction, you have learned nothing about which one caused it.

Timing and administration

BPC-157 is usually described as twice-daily subcutaneous administration, with injections placed as close to the injury site as is reasonable. TB-500 is typically described twice weekly rather than daily, reflecting its longer apparent activity window.

A note worth being honest about: injecting near an injury is standard practice in this community, but the evidence that it improves outcomes over a distant injection site does not exist. It is a reasonable assumption derived from the local-action mechanism, not a finding.

Pairing with actual rehabilitation

This is the part most protocols online skip. A peptide that accelerates tissue repair does so in the context of the mechanical load you place on the tissue. Accelerated healing without progressive loading produces tissue that is repaired but not strong.

The practical implication: a recovery protocol without a structured rehabilitation programme is doing half the job, and arguably the less important half. Loading progression, range-of-motion work and graded return to activity are what convert repaired tissue into functional tissue.

What the evidence actually supports

Supported by consistent animal data: accelerated healing of induced tendon, ligament and muscle injuries; reduced scar formation; improved vascularisation at injury sites.

Not supported by human trial data: the specific doses listed above, the injection-near-injury approach, the loading-then-maintenance structure, and most of the timelines quoted.

There is no randomised controlled human trial of this combination that anyone can point to. Every protocol you read, including this one, is a description of practice that emerged from preclinical findings, not a validated clinical approach.

The confidence with which recovery protocols are described online is inversely related to the amount of human data behind them.

Where to be specifically careful

Both BPC-157 and TB-500 have mechanisms that touch cell proliferation and angiogenesis. In anyone with an active malignancy or a history of proliferative disease, that is a genuine reason to stop and speak to an oncologist rather than proceed. TB-500's parent protein, thymosin beta-4, is upregulated in several tumour types — a mechanistic flag, not proof of harm, but not nothing either.

Reasonable expectations

If you read a recovery protocol promising dramatic change within a week, you are reading marketing. The preclinical timelines translate to weeks, not days, and the outcome depends far more on the nature of the injury and the quality of rehabilitation than on the compounds.

Dosing context

What is reported, and by whom

Study & clinical-use amounts

Neither compound has ever been dosed in a controlled human trial. The figures that circulate as "study doses" for BPC-157 come from rodent work scaled by users, not from human studies. TB-500's human safety profile has drawn regulatory concern, and there is no approved dose of either.

Where a compound has no human dose-finding study, there is no study-reported amount to quote — only community numbers, which are shown separately and labelled unverified.

Community-reported · unverified

**BPC-157:** 250–500 mcg daily by injection, split into one or two doses; oral capsules at 500–1,000 mcg daily for gut symptoms. **TB-500:** 2–2.5 mg twice weekly for two to four weeks, then 2–2.5 mg monthly as maintenance. The reported pattern is the combination, not either compound alone. These figures come from public forum posts, have never been studied, and are not a recommendation.

These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.

Where the reported amounts come from

Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.

Preclinical & non-clinical data

BPC-157: rodent models of tendon, ligament, muscle, gut-lining and nerve injury, plus cell studies on fibroblast migration and vessel formation, consistent across several labs. TB-500: wound healing, corneal repair, tendon and muscle injury models in rodents, plus cardiac and cell work that raised a human safety flag. Both bodies of work are preclinical. They support interest, not use.

Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.

Reported experiences

What people in these communities describe

Public anecdotal reports

This pairing has the largest public reporting base of any stack on the site, and the accounts are remarkably consistent in shape: a two- to four-week course for a specific injury, a return to training, and a clear feeling that the timeline was compressed. Equally consistent are the caveats users write themselves — that tendons heal slowly anyway, that they could not tell which of the two compounds did the work, and that they restarted training at the same time.

What people report noticing: less pain on movement, easier mornings after training, and in gut-focused accounts, calmer digestion. What they report disliking: flu-like feelings and headaches after TB-500 doses, injection-site irritation, and occasional lightheadedness with BPC-157. Nobody in these threads has imaging or clinical follow-up. That is the whole evidence base of the combination, and it is why this guide keeps the trial literature separate from the anecdotes.

Where these reports come from

These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.

Referenced in this guide

Compounds mentioned

Open a dossier for the mechanism, dosing reference, side effects and the primary sources.

BPC-157

Body Protection Compound 157 — pentadecapeptide

Beginner

Repair & Recovery

The repair peptide the rest of the field is measured against.

RecoveryInjuryGut
Open dossier

TB-500

Thymosin Beta-4 fragment

Intermediate

Repair & Recovery

Systemic repair signalling, rather than site-specific.

RecoveryInjuryFlexibility
Open dossier

GHK-Cu

Copper tripeptide-1

Beginner

Skin & Aesthetics

A copper-binding tripeptide with a long cosmetic history.

SkinCollagenHair
Open dossier
Keep reading

More intermediate protocols

IntermediateStacking

Stacking Structure: How to Combine Compounds Without Guessing

The principles that determine whether a stack is coherent or arbitrary — receptor independence, overlapping effects, and the discipline of introducing one thing at a time.

10 min read

IntermediateProtocols

Cycle Planning, Timing and Washout

Why protocols are structured as cycles rather than continuous use, how timing within the day changes the response, and how to plan a washout properly.

9 min read